LATEST NEWS

 

                    

Nutritional Soup for Cancer

An enormous amount of scientific literature shows beyond a reasonable doubt that many components of fruits, vegetables, herbs and mushrooms have the ability to retard and treat cancer—at least in animals and test tubes.1-5 Similar results in human studies, on the other hand, are few and far between, primarily because human studies have yet to be performed. One exception was the fish-oil study reported in the January 1998 issue of Cancer, in which a large, well-designed, double-blind study showed fish oil more than doubled the survival time of patients with advanced cancers of the breast, colon, lung and pancreas.6 Tragically, these encouraging results did not catch the interest of the medical profession, the media or the public. Nor did the big cancer organizations and institutions put their prestige or money on the line in order to replicate the study. Perhaps their interest will perk up with news of a nutritional broth that may have tripled the survival time of patients with advanced non-small cell lung cancer.

 

Non-small cell lung cancer kills more than 400,000 Americans each year. Knowing conventional therapies are only marginally effective in treating this condition,7 researchers at the Connecticut Institute for Aging and Cancer in Milford along with those at the Czech Republic's University of Palacky tested an experimental nutritional treatment on six patients with advanced (Stage III or Stage IV) non-small cell lung cancer compared to 13 comparable lung cancer victims who did not receive the treatment. The design, however, was not double-blind, meaning both patients and doctors knew who had received the therapy and who had not. Regardless of which group patients were in, each continued their standard chemotherapy treatments.

 

The researchers' experimental cancer treatment was nothing more or less than 30 g a day of soup stock prepared from a broad array of herbs, vegetables and mushrooms, including soybeans, shiitake mushrooms (Lentinus edodes), mung beans, red dates, scallions, garlic (Allium sativum), lentils, leeks, hawthorn fruit (Crataegus pinnatifida), onions, ginseng (Panax spp.), angelica root (Angelica spp.), licorice (Glycyrrhiza spp.), dandelion root (Taraxacum officinale), senegal root (Polygala senega), ginger (Zingiber officinalis), olives, sesame seeds and parsley. The complex is now a commercially available product produced in Milford, Conn.

 

Although vegetable soup chemotherapy may sound silly, a 24-month follow-up revealed remarkable results. For example, control patients lost an average of 11.6 percent of their body weight, while those taking the vegetable soup lost only 2.1 percent. Moreover, vegetable soup patients scored much higher on their day-to-day quality of life function tests as measured by the standard Karnofsky Performance Scale (KPS). Among control subjects, KPS scores fell from a respectable 78 at the start to a struggling 55 within three months, while the vegetable soup patients' average score actually improved from 75 at the start to a follow-up value of 80.

 

The most impressive result of this study, however, was the apparent survival advantage of those taking the experimental broth. Excluding three patients who died early, the median survival among the remaining 10 control patients was 4.5 months, with a 95 percent confidence range of four to seven months. In contrast, half the soup patients were still alive at 15.5 months, with a 95 percent confidence range of nine to 18 months. Thus, the broth treatment more than tripled the median survival rate, far surpassing the power of any conventional therapy.

 

Of course, these wonderful results could be a fluke. Larger, double-blind and better-controlled studies may show that vegetable soup is not, in fact, effective as a cancer treatment. But considering there is a chance that it may be, the question is whether such pivotal research will actually be performed.

 

Preliminary signs do offer a smidgen of hope, as the research report itself acknowledges several internationally respected leaders of the orthodox cancer elite. Perhaps one or more of these "union" leaders will place their personal prestige on the line in order to vouch for continued research into the role herbs, fruits and vegetables play in cancer prevention and cure. If so, a large double-blind study could start promptly, and, given the deadly nature of lung cancer, the results would follow quickly. The interests of both patients and scientists would be served by determining if a bowl of mere vegetable soup has the power to double as a chemotherapy treatment.

 

Richard N. Podell, M.D., M.P.H., is director of the Podell Medical Center in New Providence, N.J.

 

References

 

1. Hartwell JL. Plants used against cancer: a survey. (Lloydia; 1971. p 30:379-416; 31:71-170, 32: 70-107, 153-205, 247-96—1969. 33:97-194, 288-92—1970. 34:103-60, 204-55, 301-60, 368-438—1971.

 

2. Evans SM, et al. Protection against metastasis of radiation-induced thymic lymphosarcoma and weight loss in C57BL/6NCrlBR mice by an autoclave resistant factor present in soybeans. Radiat Res 1992;132:259-62.

 

3. Peterson G. Genistein and biochanin A inhibit the growth of human prostate cancer cells not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 1993;22:335-45.

 

4.Shamsuddkin AM, Ullah A. Suppression of large intestinal cancer in F344 rats by inositol hexaphosphate. Carcinogenesis 1988;9:577-80.

 

5. Chihara G, et al. Antitumor and metastasis-inhibitory activities of lentinan as an immunomodulator: an overview. Cancer Detect Prev Suppl 1987;1:423-43.

 

6. Gogos C, et. al. Dietary Omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial. Cancer 1998;82:395-402.

 

7. Sun AS, et al. Phase I/II study of stage II and IV non-small cell lung cancer patients taking a specific dietary supplement. Nutr Cancer 1999;34(1):62-9.

 

 

 

 

Tough on crime, to hell with the causes of crime if they make money

Research shows a direct link between junk food and violent behaviour. But governments are in cahoots with the industry

George Monbiot
Tuesday May 2, 2006
The Guardian


 

Does television cause crime? The idea that people copy the violence they watch is debated endlessly by criminologists. But this column concerns an odder and perhaps more interesting idea: if crime leaps out of the box, it is not the programmes that are responsible as much as the material in between. It proposes that violence emerges from those blissful images of family life, purged of all darkness, that we see in the advertisements.

Let me begin, in constructing this strange argument, with a paper published in the latest edition of Archives of Pediatrics and Adolescent Medicine. It provides empirical support for the contention that children who watch more television eat more of the foods it advertises. "Each hour increase in television viewing," it found, "was associated with an additional 167 kilocalories per day." Most of these extra calories were contained in junk foods: fizzy drinks, crisps, biscuits, sweets, burgers and chicken nuggets. Watching television, the paper reported, "is also inversely associated with intake of fruit and vegetables".

There is no longer any serious debate about what a TV diet does to your body. A government survey published last month shows that the proportion of children in English secondary schools who are clinically obese has almost doubled in 10 years. Today, 27% of girls and 24% of boys between 11 and 15 years old suffer from this condition, which means they are far more likely to contract diabetes and to die before the age of 50. But the more interesting question is what this diet might do to your mind. There are now scores of studies suggesting that it hurts the brain as much as it hurts the heart and the pancreas. Among the many proposed associations is a link between bad food and violent or antisocial behaviour.

The most spectacular results were those reported in the Journal of Nutritional and Environmental Medicine in 1997. The researchers had conducted a double-blind, controlled experiment in a jail for chronic offenders aged between 13 and 17. Many of the boys there were deficient in certain nutrients. They consumed, on average, only 63% of the iron, 42% of the magnesium, 39% of the zinc, 39% of the vitamin B12 and 34% of the folate in the US government's recommended daily allowance. The researchers treated half the inmates with capsules containing the missing nutrients, and half with placebos. They also counselled all the prisoners in the trial about improving their diets. The number of violent incidents caused by inmates in the control group (those taking the placebos) fell by 56%, and in the experimental group by 80%. But among the inmates in the placebo group who refused to improve their diets, there was no reduction. The researchers also wired their subjects to an electroencephalograph to record brainwave patterns, and found a major decrease in abnormalities after 13 weeks on supplements.

A similar paper, published in 2002 in the British Journal of Psychiatry, found that among young adult prisoners given supplements of the vitamins, minerals and fatty acids in which they were deficient, disciplinary offences fell by 26% in the experimental group, and not at all in the control group. Researchers in Finland found that all 68 of the violent offenders they tested during another study suffered from reactive hypoglycaemia: an abnormal tolerance of glucose caused by an excessive consumption of sugar, carbohydrates and stimulants such as caffeine.

In March this year the lead author of the 2002 report, Bernard Gesch, told the Ecologist magazine that "having a bad diet is now a better predictor of future violence than past violent behaviour ... Likewise, a diagnosis of psychopathy, generally perceived as being a better predictor than a criminal past, is still miles behind what you can predict just from looking at what a person eats."

Why should a link between diet and behaviour be surprising? Quite aside from the physiological effects of eating too much sugar (apparent to anyone who has attended a children's party), the brain, whose function depends on precise biochemical processes, can't work properly with insufficient raw materials. The most important of these appear to be unsaturated fatty acids (especially the omega 3 types), zinc, magnesium, iron, folate and the B vitamins, which happen to be those in which the prisoners in the 1997 study were most deficient.

A report published at the end of last year by the pressure group Sustain explained what appear to be clear links between deteriorating diets and the growth of depression, behavioural problems, Alzheimer's and other forms of mental illness. Sixty per cent of the dry weight of the brain is fat, which is "unique in the body for being predominantly composed of highly unsaturated fatty acids". Zinc and magnesium affect both its metabolism of lipids and its production of neurotransmitters - the chemicals which permit the nerve cells to communicate with each other.

The more junk you eat, the less room you have for foods which contain the chemicals the brain needs. This is not to suggest that food advertisers are solely responsible for the decline in the nutrients we consume. As Graham Harvey's new book We Want Real Food shows, industrial farming, dependent on artificial fertilisers, has greatly reduced the mineral content of vegetables, while the quality of meat and milk has also declined. Nor do these findings suggest that a poor diet is the sole cause of crime and antisocial behaviour. But the studies I have read suggest that any government that claims to take crime seriously should start hitting the advertisers.

Instead, our government sits back while the television regulator, Ofcom, canoodles with the food industry. While drawing up its plans to control junk food adverts, Ofcom held 29 meetings with food producers and advertisers and just four with health and consumer groups. The results can be seen in the consultation document it published. It proposes to do nothing about adverts among programmes made for children over nine and nothing about the adverts the younger children watch most often. Which? reports that the most popular ITV programmes among two- to nine-year-olds are Dancing on Ice, Coronation Street and Emmerdale, but Ofcom plans to regulate only the programmes made specifically for the under-nines. It claims that tougher rules would cost the industry too much. To sustain the share values of the commercial broadcasters, Ofcom is prepared to sacrifice the physical and psychological wellbeing of our children.

At the European level, the collusion is even more obvious. Last week, Viviane Reding, the European media commissioner, spoke to a group of broadcasters about her plans to allow product placement in European TV programmes (this means that the advertisers would be allowed to promote their wares during, rather than just between, the programmes). She complained that her proposal had been attacked by the European parliament. "You have to fight if you want to keep it," she told the TV executives. "I would like to make it very clear that I need your support in this."

I spent much of last week trying to discover whether the Home Office is taking the research into the links between diet and crime seriously. In the past, it has insisted that further studies are needed, while failing to fund them. First my request was met with incredulity, then I was stonewalled. Tough on crime. To hell with the causes of crime.

www.monbiot.com

 

Journals 'regularly publish fraudulent research'

David Batty
Wednesday May 3, 2006


 
Fraudulent research regularly appears in the 30,000 scientific journals published worldwide, a former editor of the British Medical Journal (BMJ) said today.

Even when journals discover that published research is fabricated or falsified they rarely retract the findings, according to Richard Smith, who was also chief executive of the BMJ publishing group.

When journals decide not to publish studies because they suspect misconduct, they often fail to alert the researchers' employers or medical authorities, such as the Department of Health and the General Medical Council, he added.

Writing in the latest edition of the Journal of the Royal Society of Medicine, Dr Smith called on editors to blow the whistle on bad research and to use their clout to pressure universities into taking action against dodgy researchers.

"In many ways editors are privileged 'whistleblowers' with the power to publish and expose institutions who fail to investigate alleged research misconduct," he said.

But the former BMJ editor said it was likely that research fraud was "equally common" in the 30,000 plus scientific journals across the globe but was "invariably covered up".

His call for action comes in the wake of several high profile cases of fraudulent research, including the Korean scientist Hwang Woo-suk who fabricated stem cell research that it was claimed would open up new ways to treat diseases like Parkinson's.

Dr Smith criticised the failure of scientific institutions, including universities, to discipline dodgy researchers even when alerted to problems by journals.

"Few countries have measures in place to ensure research is carried out ethically," he said.

"Most cases are not publicised. They are simply not recognised, covered up altogether or the guilty researcher is urged to retrain, move to another institution or retire from research."

Dr Smith called for the UK Research Integrity Office, launched last month to develop a code of practice for researchers, to be given stronger powers to investigate allegation of fraudulent or unethical work.

The Committee on Publication Ethics, which advises scientific journals, estimates that there are about 50 cases of seriously fraudulent research in major institutions in Britain a year.



 

 

September 30th, 2004 8:43 pm
Health-care firms on lookout for Michael Moore

By Bruce Japsen / Chicago Tribune

The latest buzz in the health-care industry has nothing to do with new drugs or medical treatments.

It's all about moviemaker Michael Moore and where he's lurking these days.

Some of the nation's biggest drug manufacturers and health insurance plans confirm they have issued warnings to their sales representatives and other employees in recent weeks, telling them to be on the lookout for the shaggy filmmaker in his trademark baseball cap. And, under no circumstances, are they to talk to Moore.

The industry's red alert was prompted by word that Moore plans to aim his camera lens at the health-care industry, much as he did with other targets, most recently President Bush in "Fahrenheit 9/11."

The $100 million box office documentary-style film presented Bush's war on terror as ill-advised and corrupt, angering the president's supporters while drawing cheers from Bush foes.

The planned movie, tentatively titled "Sicko," is expected to focus on health-care industry business practices, specifically those of the managed-care and pharmaceutical industries, which have both been mentioned in Moore's recent speeches and interviews, his spokesman said.

Health-care companies are hardly enthused.

"What our society really needs is a serious debate about overall health care based on facts, not just another one-sided micro-mockumentary," said Court Rosen, spokesman with the drug industry's Washington lobby, Pharmaceutical Research and Manufacturers of America.

But Moore's people seemed amused by the industry's call to arms, saying health-care companies obviously have reason to be concerned if they feel the need to put their employees on guard. Moore representatives say there isn't even a timetable for production to begin, and financing has yet to be finalized.

"Everything he does is well-documented, so I can understand why they would be so worried," said Moore spokesman Mark Benoit.

Industry observers don't think it will be difficult for Moore to find real-life examples, since the business practices of HMOs and certain other health plan business practices that encourage low-cost medical care have long been criticized as short-changing patients.

Practices targeted

Meanwhile, drug industry marketing practices have been a target of prosecutors and lawmakers who say they can lead to unnecessary prescriptions by doctors or to higher health-care costs.

The industry's gift-giving practices, intended to win physician loyalty to certain drugs, have been of particular concern in a climate of growing consumer outrage over drug costs, which have risen at an annual rate of 15 percent during each of the last four years, far exceeding inflation.

"We would welcome any public disclosure on the way this multibillion-dollar industry works," said Lynda DeLaforgue, co-director of consumer group Citizen Action Illinois. "They would certainly have reason to be concerned about any group looking into their business practices, looking into the amount of money that they use to influence the political and legislative process. These are obviously the typical things Mr. Moore delves into deeper."

If industry reports on Moore sightings are to be believed, the filmmaker himself is taking a page out of drugmakers' handbooks to do his movie by offering medical professionals payments for access to their offices.

Companies have warned their sales representatives to be on the lookout for camera phones and reports of Moore representatives offering $50,000 to doctors' offices to place hidden cameras or $5,000 to sales representatives willing to be filmed, according to a representative of one drugmaker, who asked not to be identified.

Moore's spokesman would not comment on any production activity or allegations of payments to drug company employees.

Miramax, which has been mentioned in published reports as financing and distributing Moore's film on the health-care industry, said a deal is in the works but it has "yet to be finalized," a Miramax spokesman said. Miramax would not comment on Moore's plans for the film, and Moore was unavailable for comment.

In the Chicago area, the Moore film has been a topic of discussion in the public relations and marketing departments at both Abbott Laboratories of North Chicago and TAP Pharmaceutical Products Inc. of Lake Forest.

"We have communicated a reminder of our media policy," said Abbott spokeswoman Laureen Cassidy.

"If Abbott representatives are directly approached by media, we have provided them with some helpful reminders for interacting with the media," she added. "This information is shared at routine training meetings held throughout the year. We also share this information when individuals are staffing an Abbott booth at medical meetings."

Education on ethics

Even before it was reported that Moore was thinking about a movie on the health-care industry, Abbott and TAP took exhaustive measures to educate their sales forces on ethical business practices.

In 2001, TAP--a joint venture of Abbott and Takeda Pharmaceutical Co. of Japan--pleaded guilty to a charge of conspiring with doctors in the mid-1990s to bill government insurers for free samples of the prostate cancer drug Lupron and paid an industry record $885 million to settle allegations of wrongdoing.

In July, 11 current and former TAP sales representatives not covered by the 2001 settlement were either acquitted or had charges against them dismissed. The trial in federal court in Boston involved charges of illegal marketing practices.

Neither TAP nor Abbott would comment on the Moore movie. They said they do not believe they are a focus of it.

A pharmaceutical professionals' Web site, Cafepharma, has been abuzz in recent weeks about Moore sightings and rumors the famed film producer is trying to recruit pharmaceutical sales representatives for his documentary.

Health plans, too, say they are aware of the film but are not going to let it distract them from providing patient care for their subscribers.

"Michael Moore is a major Hollywood entertainer and while we have heard through the Hollywood press that he has signed a deal for his next movie, our industry is much more focused on the needs of the American people advancing a positive policy agenda in Washington and across the country to make high-quality health care affordable for millions of Americans," said Mohit Ghose, spokesman for America's Health Insurance Plans.

 

 

 

German Magazine "Spiegel" Tells the Truth About Chemo Treatment

One of the most read German magazines, Spiegel, recently published a three page article on the uselessness of chemotherapy. While oncologists tell their patients that chemo helps prolong their lives, statistics have revealed that for the most common cancers chemo does absolutely nothing. In the case of breast cancer, chemo even shortened the median life span from 24 months to 22 months, in prostate cancer from 19 months to 18 months; while the median survival time for lung cancer was increased from 5 to 6 months and from 12 to 14 months for bowel cancer. All in all, chemo does nothing for the most common kinds of cancer.

What comes as a surprise for the average reader, the pharma critical reader has known for a long time: Dr. Ralph Moss' book "questioning chemotherapy", a meta analysis of a large number of studies, revealed the same result.

Why orthodox medicine is willing to spend about 15% more on this useless and excessively expensive kind of treatment remains a mystery to most everyone with a three digit IQ, except of course for those who have realized that pharmaceutical companies are not about helping patients but about making money.